Welcome to our dedicated page for Pharmadrug news (Ticker: LMLLF), a resource for investors and traders seeking the latest updates and insights on Pharmadrug stock.
PharmaDrug Inc. (OTC Pink: LMLLF) generates news primarily around specialty pharmaceutical development, corporate strategy and financing activities. Company releases describe a focus on the research, development and commercialization of controlled-substances and natural medicines, including psychedelics and previously approved drugs, with particular emphasis on cepharanthine and its reformulated version PD-001 through majority-owned Sairiyo Therapeutics.
News updates frequently cover progress in the cepharanthine program, such as stability studies for PD-001 and regulatory milestones supporting first-in-human Phase 1 clinical studies in Australia for viral infectious diseases. These items provide context on how PharmaDrug is advancing its clinical pipeline and working with contract development and manufacturing organizations to prepare trial material.
Another recurring theme in PharmaDrug’s news flow is strategic and corporate development. The company has reported a strategic review process led by a special committee to evaluate its assets, research programs and capital structure. It has also announced decisions regarding its subsidiary SecureDose Synthetics Inc., including the decision to cease activities there and concentrate on therapeutic molecules and medical products.
Investors following LMLLF can also expect updates on PharmaDrug’s collaboration with Canurta Limited Partnership and Canurta Inc., including letters of intent, definitive agreements and tranche closings for PharmaDrug’s planned equity interest in Canurta. Financing-related news, such as the issuance or restructuring of secured convertible debentures and associated warrants, is another key category of announcements.
By reviewing this news feed, readers can monitor developments in PharmaDrug’s clinical programs, its work in natural and psychedelic medicines, its botanical therapeutics collaboration with Canurta and its ongoing capital structure and strategic review activities.
PharmaDrug (OTC: LMLLF) closed the first tranche of its acquisition of limited partnership units of Canurta, acquiring 8,109,987 LP Units in exchange for 25,980,000 PharmaDrug shares at a deemed price of $0.0152 per share on January 5, 2026.
The company issued secured convertible debentures totaling $445,686 maturing October 13, 2026, convertible at $0.05 per share; debentures bear 22% interest if unpaid at maturity. A second tranche to reach 40% Canurta ownership is planned on or before March 31, 2026, subject to shareholder approval and a rescission right expiring March 1, 2026.
PharmaDrug (OTC Pink: LMLLF) agreed to issue $445,686 principal amount of secured convertible debentures to two existing holders to replace previously matured, unpaid debentures. Each debenture will mature on October 13, 2026 and is convertible into common shares at $0.05 per share (subject to adjustment). Debentures will be secured by a general security agreement. No interest is payable unless principal is unpaid at maturity, in which case interest accrues at 22% per annum. Completion is subject to customary closing conditions, including CSE approval and required shareholder and regulatory approvals.
PharmaDrug (OTC: LMLLF) executed a definitive securities exchange agreement to acquire up to a 40% equity interest in Canurta in two tranches via issuance of an aggregate 83,645,316 PHRX shares at the 20‑day VWAP prior to each closing.
The first closing will exchange 8,109,987 Canurta LP units for 25,980,000 PHRX shares on or about Nov 10, 2025. The second closing will exchange 8,191,495 LP units for 57,665,316 PHRX shares on or before Jan 31, 2026, subject to Canadian Securities Exchange and shareholder approval; a shareholder meeting is expected in early Jan 2026.
On completion, Canurta would hold ~44% of PharmaDrug pro forma. The deal includes a recission right expiring by Mar 1, 2026 and forgivable promissory notes of $85,000 at each closing bearing 12% interest to support working capital.
PharmaDrug (OTC:LMLLF) has issued a correction to its July 30, 2025 news release regarding its LOI to acquire equity interest in Canurta Inc. The company clarified that the second tranche will involve 57,665,316 shares (not 32,827,438 as previously stated) and the total share issuance will be 83,645,316 (not 58,807,438).
The corrected deal structure involves PharmaDrug acquiring 40% equity in Canurta through two tranches (19.9% and 20.1%). Upon completion, Canurta will hold approximately 44% of PharmaDrug's shares. The transaction includes $85,000 contributions from Canurta per tranche and the appointment of Canurta's CEO, Akeem Gardner, to PharmaDrug's Board upon first tranche closing.
PharmaDrug (OTC:LMLLF) has signed a non-binding Letter of Intent to acquire up to 40% equity interest in Canurta Limited Partnership, a biotechnology company focused on botanical drugs for inflammation and neurodegenerative diseases. The acquisition will be executed in two tranches of 19.9% and 20.1%, respectively.
The deal structure involves PharmaDrug issuing a total of 58,807,438 shares, with Canurta receiving approximately 44% ownership of PharmaDrug's outstanding shares. Canurta will contribute $85,000 per tranche through non-interest-bearing promissory notes. Upon first tranche completion, Canurta's CEO Akeem Gardner will join PharmaDrug's Board of Directors.
PharmaDrug has completed the issuance of $412,552.94 in debentures to replace outstanding secured convertible debentures, along with 8,251,058 common share purchase warrants. The new debentures will mature on September 30, 2025, and are convertible into common shares at $0.05 per share. The debentures are secured by a general security agreement and will bear 22% annual interest only if unpaid at maturity. The accompanying warrants allow holders to purchase shares at $0.05 for two years. All securities are subject to a four-month hold period until March 16, 2025.
PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) announces the issuance of $414,523 in debenture units to replace outstanding secured convertible debentures. The new debentures will mature on September 30, 2025, and are convertible into common shares at $0.05 per share. The company will also issue 8,290,000 common share purchase warrants. No interest will be charged unless principal remains unpaid at maturity, triggering a 22% annual interest rate. The warrants allow holders to purchase shares at $0.05 for two years after issuance.
PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) has announced the successful completion of a stability study for its patented enteric-coated cepharanthine formulation (PD-001). The six-month accelerated condition study, conducted at 40°C and 75% relative humidity by Genvion , demonstrated acceptable stability parameters for PD-001 in both bottle and encapsulated forms. This achievement supports the manufacturing of clinical trial material for the company's upcoming first-in-human Phase 1 clinical study targeting viral infectious diseases. The study follows the August 2024 approval from the Australian Human Research Ethics Committee to initiate the clinical trial through Sairiyo Therapeutics, which is 51% owned by PharmaDrug and 49% by PharmaTher Holdings.
FAQ
What is the current stock price of Pharmadrug (LMLLF)?
What is the market cap of Pharmadrug (LMLLF)?
